

Form 51-102F3
MATERIAL CHANGE REPORT

1. **Name and address of the Company.**

CHROMEDX CORP. (the “Company”)
65 Queen Street West
Suite 520
Toronto, Ontario M5H 2M5

2. **Date of Material Change.**

July 10, 2015

3. **News Release.**

Press release disclosing the material change was released on July 10, 2015, through the facilities of Newsfile Corp.

4. **Summary of Material Change.**

The Company announced that it had completed its previously announced non-brokered private placement (the “Offering”) for gross proceeds of CDN\$1,143,681.50 through the issuance of 9,149,452 units (each a “Unit”) at a price of CDN\$0.125 per Unit. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”), each Warrant entitling the holder thereof to acquire one Common Share at a price of \$0.20 for a period of eighteen (18) months from the closing date.

5. **Full Description of Material Change.**

The material change is fully described in the Company’s press release which is attached as Schedule “A”.

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102.**

The report is not being filed on a confidential basis.

7. **Omitted Information.**

No significant facts have been omitted from this Material Change Report.

8. **Executive Officer.**

Wayne Maddever, Chief Executive Officer.

9. **Date of Report.**

This report is dated at Toronto, this 14th day of July, 2015.

CHROMEDX CORP.

Per: Wayne Maddever (Signed)
Wayne Maddever, CEO

SCHEDULE "A"

CHROMEDX CORP.

65 Queen St. W., Suite 520
Toronto, ON M5H 2M5

NEWS RELEASE

July 10, 2015
For Immediate Release
Toronto, Canada

CSE: CHX

CHROMEDX CORP. CLOSSES PRIVATE PLACEMENT OF UNITS

July 10, 2015 – ChroMedX Corp. (the "**Company**") (CSE: CHX) is pleased to announce that it has completed its previously announced non-brokered private placement (the "**Offering**") for gross proceeds of CDN\$1,143,681.50 through the issuance of 9,149,452 units (each a "**Unit**") at a price of CDN\$0.125 per Unit. Each Unit is comprised of one common share of the Company (a "**Common Share**") and one Common Share purchase warrant (a "**Warrant**"), each Warrant entitling the holder thereof to acquire one Common Share at a price of \$0.20 for a period of eighteen (18) months from the closing date.

In connection with the Offering, the Company also paid an aggregate of \$4,250.00 in cash commissions and has issued 34,000 broker warrants ("**Broker Warrants**") to certain parties for introducing purchasers to the Company. Each Broker Warrant entitles the holder thereof to purchase one Common Share at a price of CDN\$0.20 for a period of 18 months from the closing date.

The securities issued in connection with the Offering will have a four month and one day hold period pursuant to applicable securities laws.

About ChroMedX

ChroMedX is an early stage company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing. Application of the devices is extended to address special requirements for neonatal care.

For further information, please contact Wayne Maddever, CEO at 647-872-9982 or Clark Kent, Corporate Development, 647-519-2646, ckent@chromedx.com Website: www.chromedx.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.